Navigation Links
mPhase to Pursue Licensing Opportunities for its Smart Drug Delivery System
Date:4/9/2013

LITTLE FALLS, New Jersey, April 9, 2013 /PRNewswire/ --

mPhase Technologies, Inc. (OTCBB: XDSL) said today that it is pursuing licensing opportunities for its Smart Drug Delivery System. mPhase recently filed a United States Letter Patent application for its novel drug delivery system based on its Smart Surface technology.

The drug delivery patent is based on mPhase's Smart Surface technology enabling the precise control of a fluid on a porous nano-structured surface.

The drug delivery system generally relates to a drug delivery system for automatically dispensing a pre set dosage of a drug agent or medication.

Many individuals require routine application of various medication and drug agents that could benefit from a drug delivery system that could be preprogrammed for automatically dispensing a pre-set dosage of a drug agent or medication.

About mPhase Technologies, Inc.

mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website: http://www.mpowertech.com. More information about the company can be found at http://www.mPhaseTech.com.

Forward-Looking Statements

As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.

Contact:

mPhase Technologies, Inc.
http://www.mPhaseTech.com
info@mphasetech.com
+1-973-256-3737


'/>"/>
SOURCE mPhase Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
2. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
3. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
4. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
5. Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends
6. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
7. Phase 3 Topical Drug for Raynauds Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
8. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
9. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
10. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
11. Parker Signs Licensing Agreement with Vanderbilt for Exoskeleton Technology and Targets Commercial Launch in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 Mederi Therapeutics today announced the ... 2468 patients who received  Stretta Therapy  to treat ... Systematic Review and Meta-Analysis of Controlled and Prospective ... of Gastroesophageal Reflux Disease ", was published in ... , MD, head of the Esophageal and Swallowing ...
(Date:2/27/2017)... Feb. 27, 2017  International Biophysics Corporation, a global medical ... today announced a 34% revenue growth in 2016 when compared ... unit sales.  This growth was fueled by its AffloVest® sales ... to the expansion of its global sales of surgical product ... CEO, "As we enter our 25 th year in ...
(Date:2/27/2017)... 2017  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ... 37 th Annual Healthcare Conference on Monday, March ... Boston, MA. A live webcast of Infinity,s ... Infinity,s website at www.infi.com , and will be ... About Infinity,Infinity is an innovative biopharmaceutical company dedicated to ...
Breaking Medicine Technology:
(Date:2/27/2017)... Linda, Ca (PRWEB) , ... February 27, 2017 ... ... Life Sciences, provides an overview on laser diffraction analysis as a tool to ... its capabilities, significance and potential to obtain improved results and novel scientific findings. ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast ... in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the ... Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... 25, 2017 , ... The February 13, 2017, assassination of Kim Jong-nam, the ... agents and the deadly use of chemical weapons. Many questions exist about the effect ... doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and ...
Breaking Medicine News(10 mins):